Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
24/7 Wall St3h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
FiercePharma5d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
BioSpace2d
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Yahoo Finance8h
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
While 80% of companies cover diabetes drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY ... Still life of the big three injectable prescription weight loss medicines, Ozempic, Victoza, and ...
3 Cheap Stocks: Nike, Teva, And Novo Nordisk
From a historical perspective, Nike (NKE) is a cheap stock to consider. The retailer, best known for its athletic shoes, lost ...
pharmaphorum3d
Novo Nordisk’s Victoza gets FDA okay for paediatric use
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.